Project Grant K01AI182503

Award Date 9/1/24
Completion Date 8/31/29
Dollars Obligated $128K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program provides $427,000 to The Johns Hopkins University to conduct longitudinal, observational studies to visualize lesional antibiotic exposures and lung fibrosis in patients with recently diagnosed pulmonary tuberculosis (TB), with or without HIV coinfection. The goal is to better characterize post-TB lung disease sequelae and identify key...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to integrate single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping to characterize the immune response to tuberculosis (TB). The $517,185 award, with a performance period from Aug 1, 2024 to Jun 30, 2026, will fund the generation of multi-omic data from 225...
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,817,044 in funding to the University of Massachusetts Medical School (UMass Medical) to conduct research on the systems genetics of tuberculosis. The grant supports a multifaceted research program that aims to understand the complex biological determinants of tuberculosis infection outcomes, leveraging...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to optimize the implementation of digital x-ray technology with computer-aided detection (CAD) for community-based tuberculosis (TB) screening in sub-Saharan Africa. The $198,720 award will fund research to evaluate two novel screening strategies against the current standard approach: individually adjusting the CAD...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $127,980.00 to The Johns Hopkins University for a five-year research project focused on integrating genomic and spatial data to develop more effective and efficient community-based tuberculosis (TB) screening and prevention interventions.

The key objectives are to: 1) Refine estimates of subnational TB prevalence by synthesizing emerging data sources; 2) Use genomic data to identify key populations with concentrated Mycobacterium tuberculosis transmission; and 3) Project the impact and cost-effectiveness of targeted TB screening and prevention approaches. The research will leverage cell phone mobility data, genomic sequencing, spatial epidemiology, and mathematical modeling to inform more evidence-based TB policymaking and accelerate progress against this leading global infectious disease threat.

Generated 7/1/25, 3:51 AM